IMJUDO 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
PSUSA/11038
Periodic Safety Update EU Single assessment - 
14/12/2023 
16/02/2024 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202304 
tremelimumab 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/11038/202304. 
WS/2543 
This was an application for a variation following a 
14/12/2023 
16/02/2024 
SmPC 
Based on the results from study D419EC00001 in children 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
and adolescents, sections 4.2, 5.1, and 5.2 have been 
updated. The efficacy and safety of of durvalumab in 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
Update of sections 4.2, 5.1 and 5.2 of the SmPC in 
order to include paediatric information based on final 
results from study D419EC00001 “Phase I/II, Open-
Label, Multicenter Study to Evaluate the Safety, 
Tolerability, and Preliminary Efficacy of Durvalumab 
Monotherapy or Durvalumab in Combination with 
Tremelimumab in Pediatric Patients with Advanced 
Solid Tumors and Hematological Malignancies”. In 
addition, the MAH took this opportunity to introduce 
editorial changes. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
combination with tremelimumab in children were assessed 
but not established. Currently available data are reported in 
the SmPC. In the dose-expansion phase, an Overall 
Response Rate of 5.0% (1/20 patients) was reported in the 
evaluable for response analysis set. No new safety signals 
were observed relative to the known safety profiles of 
durvalumab and tremelimumab in adults. 
For more information, please refer to the Summary of 
Product Characteristics. 
IG/1659 
A.5.a - Administrative change - Change in the name 
04/09/2023 
16/02/2024 
Annex II and 
and/or address of a manufacturer/importer 
responsible for batch release 
PL 
II/0001 
Extension of indication to include in combination with 
22/06/2023 
04/08/2023 
SmPC, 
Please refer to Scientific Discussion ‘Imjudo-H-C-6016-II-
durvalumab and platinum-based chemotherapy, the 
Labelling and 
0001’ 
first-line treatment of adults with metastatic non-
small cell lung cancer (NSCLC) with no sensitising 
EGFR mutations or ALK positive mutations for 
Imjudo, based on the final analysis from the pivotal 
study D419MC00004, a Randomised, Multi-center, 
Open-Label, Comparative Global Study to Determine 
the Efficacy of Durvalumab or Durvalumab and 
Tremelimumab in Combination with Platinum-Based 
Chemotherapy for First-Line Treatment in Patients 
PL 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
with Metastatic Non Small-Cell Lung Cancer (NSCLC) 
(POSEIDON). As a consequence, sections 2, 4.1, 4.2, 
4.4, 4.5, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are 
updated. The Package Leaflet is updated in 
accordance. In addition, the MAH took the 
opportunity to include minor editorial changes. 
The variation leads to amendments to the Summary 
of Product Characteristics and Package Leaflet. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
Page 3/3 
 
 
 
 
 
 
 
 
